Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 14, 2023, Homology Medicines, Inc. (the "Company") held its Annual
Meeting of Stockholders. A total of 45,565,496 shares of common stock were
present online or represented by proxy at the meeting, representing
approximately 78.84% percent of the Company's outstanding common stock as of the
April 17, 2023 record date. The following are the voting results for the
proposals considered and voted upon at the meeting, all of which were described
in the Company's definitive proxy statement filed with the Securities and
Exchange Commission on April 28, 2023.
Item 1 - Election of two Class II Directors to serve until the Company's 2026
Annual Meeting of Stockholders, and until their respective successors have been
duly elected and qualified.
Votes Votes Broker
NOMINEE FOR WITHHELD Non-Votes
Steven Gillis, Ph.D. 32,246,621 2,619,932 10,698,943
Albert Seymour, Ph.D. 34,681,867 184,686 10,698,943
Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the
Company's independent registered public accounting firm for the year ending
December 31, 2023.
Votes Votes Votes Broker
FOR AGAINST ABSTAINED Non-Votes
44,765,597 108,239 691,660 0
Based on the foregoing votes, Steven Gillis, Ph.D. and Albert Seymour, Ph.D.
were elected as Class II Directors and Item 2 was approved.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses